Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minStrong Bearish
5 minExpanding
Daily trend turns down below $18.32
Key levels
Resistance$21.26
Resistance$19.78
Support$18.32
Support$17.33
Latest news & SEC filings
AnalystMorgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42
AnalystWedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24
AnalystWedbush lifts Denali Therapeutics target to $24 from $23
All DNLI news →Denali Therapeutics is a biopharmaceutical company that discovers and develops medicines for neurodegenerative diseases and lysosomal storage disorders. Its proprietary TransportVehicle technology is designed to carry large molecules such as enzymes, oligonucleotides, and antibodies across the blood-brain barrier. Its pipeline includes treatments for Hunter syndrome, Sanfilippo syndrome type A, frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and Pompe disease. The company operates in the United States and collaborates with partners including Biogen, Takeda, and Sanofi.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$23.00
SEPT Mid Target
$35.00
SEPT High Target
$42.00
Analyst Consensus
$35.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DNLI.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$29.09
27
Moat Score
NONE
2/9
Piotroski Score
11.7
Altman Z-Score
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Thornberry Nancy | director | Sale | 10,824 | $247K | Sep 2, 2026 |
| Thornberry Nancy | director | Sale | 615 | $15K | Sep 2, 2026 |
| Van Hauwermeiren Timothy | director | Buy | 6,408 | - | Jun 3, 2026 |
| Thornberry Nancy | director | Buy | 6,408 | - | Jun 3, 2026 |
| Cook Jennifer E. | director | Buy | 6,408 | - | Jun 3, 2026 |
| Krognes Steve E. | director | Buy | 6,408 | - | Jun 3, 2026 |
| Schenkein David P | director | Buy | 6,408 | - | Jun 3, 2026 |
| Klein Peter S | director | Buy | 6,408 | - | Jun 3, 2026 |
| BAKER BROS. ADVISORS LP | director | Buy | 6,408 | - | Jun 3, 2026 |
| FLATLEY JAY T | director | Buy | 6,408 | - | Jun 3, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
204.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-15.56%
FCF Growth YoY
-16.1%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for DNLI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:44 | $19.73 | 1,100 | $$22K | SELL |
| 21:00:44 | $19.73 | 1,882 | $$37K | SELL |
| 21:00:44 | $19.73 | 12,978 | $$256K | SELL |
| 21:00:44 | $19.73 | 3,100 | $$61K | SELL |
| 21:00:43 | $19.73 | 3,556 | $$70K | SELL |
5 dark pool trades shown · $$446K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for DNLI, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $35 | Mar 19 | 128 | $$100 | 1 | SWEEP |
| PUT | $20 | Mar 19 | 128 | $$1240 | 4 | SWEEP |
| PUT | $20 | Jun 17 | 218 | $$420 | 1 | SWEEP |
| PUT | $20 | Jun 17 | 218 | $$420 | 1 | SWEEP |
| PUT | $20 | Nov 20 | 9 | $$160 | 2 | SWEEP |
5 options trades shown · 20% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Denali Therapeutics Inc. (DNLI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Denali Therapeutics Inc. (DNLI) is at $19.73, down 0.60% (-$0.12) at the Nov 11, 2026 close.
Latest DNLI news — Nov 4, 2026: Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42 · Nov 4, 2026: Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24
The average analyst price target for DNLI is $35.00, ranging from $23 to $42, based on 10 analysts.
Analyst ratings for DNLI: 0 Buy, 15 Hold, 0 Sell — consensus Hold.
DNLI last reported on Aug 6, 2026: EPS -$0.68 vs -$0.51 expected — a miss of 32.5%.
DNLI does not currently pay a dividend.
Support: $18.32, $17.33, $15.34. Resistance: $19.78, $21.26, $22.19.
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
Nov 4, 2026: Morgan Stanley keeps Overweight on Denali Therapeutics, lifts target to $42 · Nov 4, 2026: Wedbush keeps Outperform rating on Denali Therapeutics, lifts target to $24 · Nov 4, 2026: Wedbush lifts Denali Therapeutics target to $24 from $23